| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Revenue | $467.5M | +8.5% |
| Cost of Revenue | $79.7M | +2.4% |
| Gross Profit | $387.8M | +9.9% |
| R&D Expense | $141.5M | +1.2% |
| SG&A Expense | $104.3M | -7.4% |
| Operating Income | -$59.8M | +37.9% |
| Pre-tax Income | -$41.8M | +46.0% |
| Income Tax | $1.8M | — |
| Net Income | -$42.7M |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $346.5M | -4.6% |
| Short-term Investments | $224.4M | +7.8% |
| Accounts Receivable | $107.3M | +6.9% |
| Current Assets | $711.7M | +1.2% |
| Total Assets | $927.3M | +0.2% |
| Current Liabilities | $369.2M | +31.1% |
| Long-term Debt | $484.5M | -1.0% |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $117.9M | +63.8% |
| Capital Expenditures | $2.8M | +29.0% |
| Investing Cash Flow | -$20.0M | +34.6% |
| Financing Cash Flow | -$116.1M | -325.1% |
| Free Cash Flow | $115.1M | +64.9% |
| +43.2% |
| EPS (Basic) | -$0.59 | +33.7% |
| EPS (Diluted) | -$0.59 | +33.7% |
| Total Liabilities |
| $779.2M |
| +4.4% |
| Stockholders' Equity | $129.8M | -24.3% |